Literature DB >> 6617404

Bilirubin-displacing effect of furosemide and sulfisoxazole. An in vitro and in vivo study in neonatal serum.

W J Cashore, W Oh, R Brodersen.   

Abstract

Sulfisoxazole and furosemide, 0.1-1.0 mM, both decreased reserve albumin concentration for bilirubin binding in pooled cord serum as estimated by rate of dialysis of 14C-monoacetyl-diamino-diphenylsulfone (MADDS) in undiluted serum at 37 degrees C. Peroxidase oxidation at a bilirubin:albumin ratio of 0.5 also showed that both drugs were capable of displacing bilirubin in vitro when added in molar excess of the albumin present. However, when aliquots of the same treated sera which had been used undiluted in the MADDS assay were diluted 40-fold and titrated with bilirubin and peroxidase, no drug-related increase in free bilirubin or decrease in reserve albumin could be shown. In vivo administration of 1 mg/kg furosemide showed no change in total bilirubin or reserve albumin by the MADDS technique in 8 infants. Estimation of the peak plasma level theoretically achievable with 1 mg/kg of furosemide suggests that peak plasma levels achieved with that dose are probably not high enough to produce significant reduction of reserve albumin, in agreement with the in vivo findings. In testing neonatal serum for bilirubin displacement by drugs, the choice of method, drug concentration, and dilution of the sample may influence the interpretation of results.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617404     DOI: 10.1159/000457309

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  7 in total

1.  Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease.

Authors:  Kevin A Strauss; Donna L Robinson; Hendrik J Vreman; Erik G Puffenberger; Graham Hart; D Holmes Morton
Journal:  Eur J Pediatr       Date:  2006-01-25       Impact factor: 3.183

2.  Principles of a competitive binding assay for the study of the interactions of poorly water-soluble ligands with their soluble binding partners. Application to bilirubin with the use of Sephadex G-10 as a competitive adsorbent.

Authors:  J A Meuwissen; M Kinnaert; G Michiels; K P Heirwegh
Journal:  Biochem J       Date:  1988-01-01       Impact factor: 3.857

Review 3.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

4.  In vitro displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycine in newborns.

Authors:  S J Wadsworth; B Suh
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

5.  Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies.

Authors:  Carl T D'Angio; William M Maniscalco
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 6.  Neonatal bilirubin toxicity. A review of kernicterus and the implications of drug-induced bilirubin displacement.

Authors:  P C Walker
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

7.  Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study.

Authors:  E Martin; S Fanconi; P Kälin; C Zwingelstein; C Crevoisier; W Ruch; R Brodersen
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.